Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits

British Journal of Pharmacology

Volumn 124, Issue 2, 1998, Pages 277-282

  Harsch, Michael ^a   Gebhardt, Angelika ^a   Reymann, Andreas ^a   Lang, Gerhard ^b   Schliack, Michael ^b   Löser, Roland ^b   Braesen, Jan Hinrich ^a   Niendorf, Axel ^a,c  

^a UNIVERSITY OF HAMBURG   (Germany)

^b ASTELLAS PHARMA INC   (Japan)

^c Institut für Pathologie   (Germany)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Campesterol; Dietary cholesterol; Lathosterol; LDL receptor; Pravastatin; WHHL rabbit

Indexed keywords

CAMPESTEROL; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PRAVASTATIN;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DENSITOMETRY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GAS LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031834496     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701831     Document Type: Article

References (54)

1. AMOROSA, L.F., ROZOVSKI, S.J., ANANTHAKRISHNAN, R., COLY, E., ALHINAI, A., MARTUCCI, C., SCHNEIDER, S.H., SHIMAMURA, T. & KHACHADURIAN, A.K. (1992). Effects of pravastatin on cholesterol metabolism in Watanabe heritable hyperlipidemic rabbits. Jpn. Heart J., 33, 451-463.
2. ANDERSEN, J.M., TURLEY., S.D. & DIETSCHY, J.M. (1982). Relative rates of sterol synthesis in the liver and various extrahepatic tissues of normal and cholesterol-fed rabbits. Relationship to plasma lipoprotein and tissue cholesterol levels. Biochim. Biophys. Acta, 711, 421-430.
3. ATKINSON, J.B., HOOVER, R.L., BERRY, K.K. & SWIFT, L.L. (1989). Cholesterol-fed heterozygous Watanabe heritable hyperlipidemic rabbits: a new model for atherosclerosis. Atherosclerosis, 78, 123-136.
4. ATKINSON, J.B., VIRMANI, R., HARRISON, J. & SWIFT, L. (1985). Pathology of atherosclerosis in heterozygous Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis, 5, 524a.
5. BILHEIMER, D.W., GRUNDY, S.M., BROWN, M.S. & GOLDSTEIN, J.L. (1983). Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. U.S.A., 80, 4124-4128.
6. BJÖRKHEM, I., MIETTINEN, T.A., REIHNÉR, E., EWERTH, S., ANGELIN, B. & EINARSSON, K. (1987). Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J. Lipid Res., 28, 1137-1142.
7. BLANKENHORN, D.H., AZEN, S.P., KRAMSCH, D.M., MACK, W.J., CASHIN-HEMPHILL, L., HODIS, H.N., DE BOER, L.W., MAHRER, P.R., MASTELLER, M.J., VAILAS, L.I., ALAUPOVIC, P. & HIRSCH, L.J. (1993). Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). Ann. Intern. Med., 119, 969-976.
8. BROWN, M.S. & GOLDSTEIN, J.L. (1986). A receptor-mediated pathway for cholesterol homeostasis. Science, 232, 34-47.
9. BUJA, L.M., KITA, T., GOLDSTEIN, J.L., WATANABE, Y. & BROWN, M.S. (1983). Cellular pathology of progressive atherosclerosis in the WHHL rabbit. An animal model of familial hypercholesterolemia. Arteriosclerosis, 3, 87-101.
10. DE CUYPER, I., WOLTHERS, B.G., VAN DOORMAAL, J.J. & WIJNANDTS, P.N. (1993). Determination of changes in serum lathosterol during treatment with simvastatin to evaluate the role of lathosterol as a parameter for whole body cholesterol synthesis. Clin. Chim. Acta, 219, 123-130.
11. DUANE, W.C. (1995). Serum lathosterol levels in human subjects reflect changes in whole body cholesterol synthesis induced by lovastatin but not dietary cholesterol. J. Lipid Res., 36, 343-348.
12. ESPER, E., CHAN, E.K. & BUCHWALD, H. (1993). Natural history of atherosclerosis and hypercholesterolemia in heterozygous WHHL (WHHL-Hh) rabbits. I. The effects of aging and gender on plasma lipids and lipoproteins. J. Lab. Clin. Med., 121, 97-102.
13. FURBERG, C.D., BYINGTON, R.P., CROUSE, J.R. & ESPELAND, M.A. (1994). Pravatsatin, lipids and major coronary events. Am. J. Cardiol., 73, 1133-1134.
14. GEBHARDT, A., PETERS, A., GERDING, D & NIENDORF, A (1994). Rapid quantification of mRNA species in ethidium bromidestained gels of competitive RT-PCR products. J. Lipid Res., 35, 976-981.
15. GOLDBERG, I., HOLLERAN, S., RAMAKRISHNAN, R., ADAMS, M., PALMER, R.H., DELL, R.B. & GOODMAN, D.S. (1990). Lack of effect of lovaststin therapy on the parameters of whole-body cholesterol metabolism. J. Clin. Invest., 86, 801-808.
16. GOLDSTEIN, J.L. & BROWN, M.S. (1989). Familial Hypercholesterolemia. In The Metabolic Basis of Inherited Disease, 6th edn. ed. Scriver, C.R., Beaudet, A.L., Sly, W.S. & Valle, D. pp. 1215-1250. New York: McGraw-Hill Information Services Company.
17. GOLDSTEIN, J.L., KITA, T. & BROWN, M.S. (1983). Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N. Engl. J. Med., 309, 288-297.
18. GRUNDY, S.M. (1988). HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med., 319, 24-33.
19. GRUNDY, S.M. & VEGA, G.L. (1985). Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J. Lipid Res., 26, 1464-1475.
20. GYLLING, H. & MIETTINEN, T.A. (1988). Serum noncholesterol sterols related to cholesterol metabolism in familial hypercholesterolemia. Clin. Chim. Acta, 178, 41-50.
21. HARSCH, M., BRAESEN, J.H. & NIENDORF, A. (1997). Effects of low-dose pravastatin sodium on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year. Atherosclerosis, 128, 139-147.
22. HAVEL, R.J., KITA, T., KOTITE, L., KANE, J.P., HAMILTON, R.L., GOLDSTEIN, J.L. & BROWN, M.S. (1982). Concentration and composition of lipoproteins in blood plasma of the WHHL rabbit. An animal model for human hypercholesterolemia. Arteriosclerosis, 2, 467-474.
23. HUETTINGER, M., SCHNEIDER, W.J., HO, Y.K., GOLDSTEIN, J.L. & BROWN, M.S. (1984). Use of monoclonal anti-receptor antibodies to probe the expression of the low density lipoprotein receptor in tissues of normal and Watanabe heritable hyperlipidemic rabbits. J. Clin. Invest., 74, 1017-1026.
24. ILLINGWORTH, D.R. (1993). How effective is drug therapy in heterozygous familial hypercholesterolemia? Am. J. Cardiol., 72, 54D-58D.
25. ISHIDA, F., SATO, A., IZUKA, Y., SAWASAKI, Y., AIZAWA, A. & KAMEI, T. (1988). Effects of MK-733, an inhibitor of 3-hydroxy3-methylglutaryl-coenzyme A reductase, on absorption and excretion of [3H]cholesterol in rabbits. Biochim. Biophys. Acta, 963, 35-41.
26. KEMPEN, H.J.M., GLATZ, J.F.C., GEVERS LEUVEN, J.A., VAN DER VOORT, H.A. & KATAN, M.B. (1988). Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J. Lipid Res., 29, 1149-1155.
27. KONDO, T. & WATANABE, Y. (1975). A heritable hyperlipidemic rabbit. Exp. Anim., 24, 89-94.
28. KOVANEN, P.T., BILHEIMER, D.W. GOLDSTEIN, J.L., JARAMILLO, J.J. & BROWN, M.S. (1981). Regulatory role for hepatic low-density lipoprotein receptors in vivo in the dog. Proc. Natl. Acad. Sci. U.S.A., 78, 1194-1198.
29. KUME, N., KITA, T., MIKAMI, A., YOKODE, M., ISHII, K., NAGANO, Y. & KAWAI, C. (1989). Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (pravastatin) and cholestyramine. Circulation, 79, 1084-1090.
30. KURODA, M., MATSUMOTO, A., ITAKURA, H., WATANABE, Y., ITO, T., SHIOMI, M., FUKUSHIGE, J., NARA, F., FUKAMI, M. & TSUJITA, Y. (1992). Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits. Japn. J. Pharmacol., 59, 65-70.
31. MAAS INVESTIGATORS. (1994). Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet, 344, 633-638.
32. MEIJER, G.W., VAN DER PALEN, J.G.P., DE VRIES, H., KEMPEN, H.J.M., VAN DER VOORT, H.A., VAN ZUTPHEN, L.F.M. & BEYNEN, A.C. (1992). Evaluation of the use of serum lathosterol to assess whole-body cholesterol synthesis in rabbits. J. Lipid Res., 33, 281-286.
33. MIETTINEN, T.A. (1970). Detection of changes in human cholesterol metabolism. Ann. Clin. Res., 2, 300-320.
34. MIETTINEN, T.A. (1991). Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor. Eur. J. Clin. Pharmacol., 40, S19-S21.
35. MIETTINEN, T.A., TILVIS, R.S. & KESANIEMI, Y.A. (1990). Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am. J. Epidemiol., 131, 20-31.
36. NIELSEN, L.B., STENDER, S. & KJELDSEN, K. (1993). Effect of lovastatin on cholesterol absorption in cholesterol-fed rabbits. Pharmacol. Toxicol., 72, 148-151.
37. PEARSON, T.A. & MARX, H.J. (1993). The rapid reduction in cardiac events with lipid-lowering therapy: Mechanisms and implications. Am. J. Cardiol., 72, 1072-1073.
38. PITT, B., MANCINI, G.B.J., ELLIS, S.G., ROSMAN, H.S & MCGOVERN, M.E. (1994). Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I)., J. Am. Coll. Cardiol., 131A, 739-742.
39. RATH, M., NIENDORF, A., REBLIN, T., DIETEL, M., KREBBER, H.-J. & BEISIEGEL, U. (1989). Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis, 9, 579-592.
40. REIHŃER, E., RUDLING, M., STÅHLBERG, L., BERGLUND, S., EWERTH, S., BJÖRKHEM, K., EINARSSON, K. & ANGELIN, B. (1990). Influence of pravastatin, a specific inhibitor of HMG-CoA-reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med., 323, 224-228.
41. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
42. SHIOMI, M., ITO, T., WATANABE, Y., TSUJITA, Y., KURODA, M., ARAI, M., FUKAMI, M., FUKUSHIGE, J. & TAMURA, A. (1990). Suppression of established atherosclerosis and xanthomas in mature WHHL rabbit by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine, Atherosclerosis, 83, 69-80.
43. SPADY, D.K. & DITSCHY, J.M. (1983). Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat. J. Lipid Res., 24, 303-315.
44. THE PRAVASTATIN MULTINATIONAL STUDY GROUP FOR CARDIAC RISK PATIENTS. (1993). Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional risk factors. Am. J. Cardiol., 72, 1031-1037.
45. TILVIS, R.S. & MIETTINEN, T.A. (1986). Serum plant sterols and their relation to cholesterol absorption. Am. J. Clin. Nutr., 43, 92-97.
46. TSUJITA, Y., KURODA, M., SHIMADA, Y., TANZAWA, K., ARAI, M., KANEKO, I., TANAKA, M., MASUDA, H., TARUMI, C., WATANABE, Y. & FUJII, S. (1986). CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta, 877, 50-60.
47. UUSITUPA, M.I.J., MIETTINEN, T.A., HAPPONEN, P., EBELING, T., TURTOLA, H., VOUTILAINEN, E. & PYÖRÄLÄ, K. (1992). Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovaststin alone and with cholestyramine or guar gum. Arterioscler. Thromb., 12, 807-813.
48. VANHANEN, H., KESANIEMI, Y.A. & MIETTINEN, T.A. (1992). Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism, 41, 588-595.
49. VANHANEN, H. & MIETTINEN, T.A. (1992). Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor levels in familial hypercholesterolaemia. Eur. J. Clin. Pharmacol., 42, 127-130.
50. VANHANEN, H.T. & MIETTINEN, T.A. (1995). Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis, 115, 135-146.
51. WATANABE, Y. (1980). Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Incidence and development of atherosclerosis and xanthoma. Atherosclerosis, 36, 261-268.
52. WATANABE, Y., ITO, T., SHIOMI, M., TSUJITA, Y., KURODA, M., ARAL, M., FUKAMI, M. & TAMURA, A. (1988). Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim. Biophys. Acta, 960, 294-302.
53. YAMAMOTO, T., BISHOP, R.W., BROWN, M.S., GOLDSTEIN, J.L & RUSSEL, D.W. (1986). Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. Science, 232, 1230-1237.
54. YAMAMOTO, T., DAVIS, CG., BROWN, M.S., SCHNEIDER, W.J., CASEY, M.L., GOLDSTEIN, J.L. & RUSSEL. D.W. (1984). The human LDL receptor: a cysteine-rich protein with multiple alu sequences in its mRNA. Cell, 39, 27-38.